Content area

|
|

Intralymfatisk allergenspecifik immunterapi

Forfatter(e)

Sara Haunstrup Næraa1, Niels-Erik Harbo Schollert2, Peter Nytofte Flader Skov2 & Preben Homøe3, 4

1) Urologisk Afdeling, Sjællands Universitetshospital, Roskilde 2) Ørelægerne Fredericia 3) Øre-, Næse-, Hals- og Kæbekirurgisk Afdeling, Sjællands Universitetshospital, Køge 4) Det Sundhedsvidenskabelige Fakultet, Københavns Universitet Ugeskr Læger 2018;180:V09170695

Reference: 
Ugeskr Læger 2018;180:V09170695
Blad nummer: 
Sidetal: 
2-5
Intralymphatic allergen-specific immunotherapy

An emerging method for allergen-specific immunotherapy is intralymphatic placement, which only requires three injections with intervals of four weeks. In this review, we summarise available evidence on clinical safety, biological efficacy and therapeutic outcomes. The treatment appears to be safe with only few and mild adverse reactions. The immunological activation profile is comparable to that known for subcutaneous therapy. Clinically, patients experienced fewer symptoms with less medication use with intralymphatic allergen-specific immunotherapy than with other types of immunotherapy. The number of studies is limited, and the studies have important limitations. More phase 3 studies are needed in order to make a conclusion.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Finn Redke | 24/04
2 kommentarer
af Christian Schlütter | 23/04
1 Kommentar
af Frede Simonsen | 20/04
2 kommentarer
af Hans Storm Erichsen | 19/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer